Fortitude Advisory Group’s Amneal Pharmaceuticals AMRX Stock Holding History

Fortitude Advisory Group’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-57	Closed	–	–	1511
2021 Q4	$0	Buy	+57	New	+$284	﹤0.01%	1545

Other funds holding AMRX

Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fortitude Advisory Group's AMRX Position: Q1 2022 in Review

Fortitude Advisory Group sold out of Amneal Pharmaceuticals (AMRX) in Q1 2022, closing a stake of 57 shares.

Fortitude Advisory Group first reported a position in AMRX in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 168 funds tracked by Wall St. Rank hold AMRX as of Q1 2022.

Fortitude Advisory Group reported no remaining Amneal Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Fortitude Advisory Group sold 57 Amneal Pharmaceuticals shares in Q1 2022.
Fortitude Advisory Group first reported a position in Amneal Pharmaceuticals in Q4 2021 and held it in 1 quarter.
Fortitude Advisory Group's Amneal Pharmaceuticals position peaked at $0 in Q4 2021.
168 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2022.

Based on Fortitude Advisory Group's 13F filing for Q1 2022, filed 25 May 2022.